Cases & Deals

  • Home
  • Practices
  • Actimis develops patent portfolio for CRTH2 and CCR3 modulators

Share

Actimis develops patent portfolio for CRTH2 and CCR3 modulators

January 2007

Client(s) Actimis Pharmaceuticals, Inc.

Representing Actimis Pharmaceuticals, Inc., Jones Day assisted with the development of patent portfolios for small molecule drugs relating to CRTH2 and CCR3 modulators.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.